News | October 21, 2009

RT Service Starts Up Adaptive Radiation Therapy for Under $5,000

October 21, 2009 - Velocity Medical Solutions, a provider of tools for clinical outcomes, radiation treatment planning and software development for oncology, has introduced a new subscription service designed to quickly provide adaptive radiation therapy to hospitals and radiation oncology centers with minimal up-front capital investment.

With less than a $5,000 up-front investment, the subscription service provides a workstation computer and all software to equip radiation oncology departments with the most advanced imaging platform available. This subscription service resulted from a new cost-effective method of product demonstration and delivery service.

The Velocity-AI Advanced Imaging Solutions system provides advanced visualization, fusion and metabolic assessment tools to better assist oncology professionals in the management of cancer patients in all stages of the treatment process. The adaptive radiation therapy platform provides dose tracking and automated re-planning tools that allow clinicians to compare dose planned to actual dose delivered throughout the treatment cycle. Adaptive re-contouring saves significant time when re-planning is required due to anatomical changes throughout a patient's treatment. Velocity-AI's deformable fusion and automated atlas-based segmentation tools allow a more accurate incorporation of diagnostic imaging into the treatment planning process and provide significant time savings in the initial contouring process. These tools represent the latest developments in clinical advancements available to oncology professionals.

The Velocity-AI Advance Imaging Solutions system enables physicians to use multi-modality imaging data sets to develop radiation therapy treatment plans.

For more information: www.VelocityMedical.com

Related Content

MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer
News | Brachytherapy Systems | January 04, 2019
Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity...
RayStation 8B Released With Machine Learning Applications for Treatment Planning
Technology | Treatment Planning | December 27, 2018
RaySearch Laboratories released RayStation 8B, the latest version of the radiation therapy treatment planning system (...
Axillary Radiotherapy and Lymph Node Surgery Yield Comparable Outcomes for Breast Cancer
News | Radiation Therapy | December 18, 2018
Early-stage breast cancer patients with cancer detected in a sentinel lymph node biopsy had comparable 10-year...
RaySearch Developing RayCommand Treatment Control System for U.K. Proton Therapy Facility
Technology | Radiation Therapy | December 10, 2018
RaySearch has decided to develop a treatment control system, RayCommand, to act as a link between its RayStation...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Sponsored Content | Videos | Radiation Oncology | November 30, 2018
Accuray's philosophy is to personalize treatments to exactly fit the patient.
Ohio State University to Open Region’s First Proton Therapy Facility

Image courtesy of The Ohio State University James Comprehensive Cancer Center

News | Proton Therapy | November 21, 2018
The Ohio State University Wexner Medical Center and the Arthur G. James Cancer Hospital and Richard J. Solove Research...